Overall, these data demonstrate that MDS patients could be good candidates for immunotherapies targeting CD8+ T cells, but treatment efficacy could be improved by the identification of appropriate therapeutic targets (e.g., tumor antigens shared by a group of patients) and a better delineation of the patient subgroups. This evidence concerns the gene CD8A and neoplasm.